Related Experiment Video
Updated: Dec 26, 2025
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
17.8K
[Anticoagulation in Venous Thromboembolism: How Long and Which Dose?]
Mariana Machado1, Sabine Ruosch-Girsberger1, Andrea Hegglin1
1Abteilung für Hämatologie, Luzerner Kantonsspital, Luzern und Universität Bern.
Praxis
|March 19, 2020
Summary
For venous thromboembolism (VTE), anticoagulation is crucial. Treatment duration and direct oral anticoagulant (DOAC) dosage require individualized risk-benefit assessment, especially for unprovoked proximal VTE or pulmonary embolism (PE).
Area of Science:
- Medicine
- Pharmacology
- Hematology
Background:
- Venous thromboembolism (VTE) is a common clinical condition requiring prompt anticoagulation.
- Direct oral anticoagulants (DOACs) are now the preferred treatment for VTE.
- Determining the optimal duration and dosage of anticoagulation for individual patients presents a significant clinical challenge.
Purpose of the Study:
- To outline key factors for deciding anticoagulation duration in VTE patients.
- To discuss considerations for dose reduction of DOACs during VTE treatment.
- To provide guidance on individualized VTE management strategies.
Main Methods:
- Review of current clinical guidelines and evidence regarding VTE treatment.
- Analysis of risk-benefit assessment for prolonged anticoagulation.
- Evaluation of factors influencing DOAC dose adjustments.
Main Results:
- Anticoagulation should generally continue for at least three months for VTE.
- Discontinuation after three months may be considered for isolated distal deep vein thrombosis (DVT).
- Extended or indefinite anticoagulation is recommended for unprovoked proximal DVT and pulmonary embolism (PE).
Conclusions:
- Individualized assessment of risks and benefits is essential for VTE treatment decisions.
- DOACs offer a primary treatment option, but careful consideration of duration and dose is necessary.
- Personalized anticoagulation strategies improve VTE management outcomes.
Keywords:
Anticoagulants oraux directs (ACOD)AntikoagulationLungenembolieMaladie thromboemboliqueTiefe VenenthromboseVenous thromboembolismVenöse Thromboembolieanticoagulationdeep venous thrombosisdirect oral anticoagulants (DOAC)direkt orale Antikoagulanzien (DOAK)embolie pulmonairepulmonary embolismthrombose veineuse profondetraitement anticoagulantMore Related Videos
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
220
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
220
01:30Venous Thrombosis IV: Nursing Management
153
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
153
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
211
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
211
01:30Venous Thrombosis I: Introduction
201
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
201